Pharmaceutical Technology Europe
Why the primary defence against biosimilars is to develop better molecules that can be launched quickly.
David E. Szymkowski
Advertisement
David E. Szymkowski is Senior Director of Biotherapeutics at Xencor.
Articles by David E. Szymkowski
Advertisement
Latest Updated Articles
- True Biosimilars Do Not Offer A Compelling Business Case
August 1st 2010
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
PharmTech Weekly Roundup—June 19, 2026
5